Abstract

Provided herein are dual-recombinant-coat-protein phage, comprising a recombinant phage genome comprising a nucleic acid encoding a polypeptide comprising a first and second distinct recombinant coat protein, wherein each recombinant coat protein comprises at least one exogenous peptide epitope selected from SEQ ID NOs: 1-498; probiotic vaccines and therapeutics comprising recombinant phage; and related methods of using same.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 39/12 - Viral antigens

Abstract

Provided herein are recombinant phage, probiotic vaccines and therapeutics comprising recombinant phage; and related methods of using same. In some embodiments, it includes recombinant phage (e.g., filamentous) and/or probiotic vaccines comprising a recombinant filamentous phage genome; and therapeutic methods of using the invention recombinant phage and/or probiotic vaccines. The invention recombinant filamentous phage: probiotic vaccines comprising said recombinant phage are useful wherein, for example, in therapeutic methods for preventing, treating, and/or reducing the risk of cancer, autoimmune diseases, respiratory diseases (e.g., asthma), neurological diseases, infectious diseases, among other diseases (osteoporosis, elevated cholesterol, among others).

IPC Classes  ?

• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 39/02 - Bacterial antigens
• C12N 15/86 - Viral vectors
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Provided herein are probiotic vaccines comprising, a recombinant filamentous phage genome comprising a nucleic acid encoding a polypeptide comprising an exogenous peptide epitope, or fragments or variants thereof, selected from the group consisting of: LPESFDGDPASNTAPLQPEQLQVF “SEQ ID NO:1; HER2”. In particular embodiments of the invention vaccine, the exogenous peptide epitope is functionally expressed on a coat protein selected from the group consisting of: pill, pVI, pVII, pVIII and pIX. Also provided herein are methods of preventing or treating cancer, comprising administering to a patient in need thereof, one or more of the probiotic vaccines provided herein: or one or more of the recombinant phages provided herein

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 15/73 - Expression systems using phage lambda regulatory sequences

Abstract

Provided herein are recombinant phage, probiotic vaccines and therapeutics comprising recombinant phage; and related methods of using same.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
• A61K 35/741 - Probiotics
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61P 35/00 - Antineoplastic agents
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Provided herein are probiotic vaccines comprising, a recombinant filamentous phage genome comprising a nucleic acid encoding a polypeptide comprising an exogenous peptide epitope, or fragments or variants thereof, selected from the group consisting of: LPESFDGDPASNTAPLQPEQLQVF "SEQ ID NO:1; HER2". In particular embodiments of the invention vaccine, the exogenous peptide epitope is functionally expressed on a coal protein selected from the group consisting of: pill, pVI. pVII. pVIII and pIX. Also provided herein are methods of preventing or treating cancer, comprising administering to a patient in need thereof, one or more of the probiotic vaccines provided herein; or one or more of the recombinant phages provided herein

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61P 35/04 - Antineoplastic agents specific for metastasis
• C12N 15/73 - Expression systems using phage lambda regulatory sequences
• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
• C12N 15/86 - Viral vectors

Abstract

Provided herein are probiotic vaccines comprising, a recombinant filamentous phage genome comprising a nucleic acid encoding a polypeptide comprising an exogenous peptide epitope, or fragments or variants thereof, selected from the group consisting of: LPESFDGDPASNTAPLQPEQLQVF "SEQ ID NO:1; HER2". In particular embodiments of the invention vaccine, the exogenous peptide epitope is functionally expressed on a coat protein selected from the group consisting of: pill, pVI, pVII, pVIII and pIX. Also provided herein are methods of preventing or treating cancer, comprising administering to a patient in need thereof, one or more of the probiotic vaccines provided herein; or one or more of the recombinant phages provided herein

IPC Classes  ?

• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
• A61K 35/74 - Bacteria
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• C12N 15/86 - Viral vectors
• A61P 35/04 - Antineoplastic agents specific for metastasis
• C12N 15/73 - Expression systems using phage lambda regulatory sequences